TP-7 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
The journey across the United States began on 15 July 1988. On the journey he slept in bushes beneath the World Trade Center, camped outside Kennedy Airport in a tent, then headed west. On Staten Island he collapsed from heat exhaustion at 105 degrees Fahrenheit. In Utah the temperatures went down to minus 30 Fahrenheit. Carrying a tent and a backpack, with no backup, he walked alone to Niagara Falls, through Ontario in Canada, to Detroit, between the Great Lakes, across the Great Plains, through the Rockies in winter, to Yellowstone National Park, then south to the Grand Canyon, on to Las Vegas, through Death Valley and then snowshoed over the Sierras to reach San Francisco. In Death Valley, down to his last $13, Skinner found $200 in the desert, and he had $1 left when he crossed the Sierras to reach Yosemite Valley. The total distance he walked from New York City to San Francisco, was 4,952 miles (7,969 km). On the journey he visited 70 hospices and appeared on television, radio and in newspapers to encourage support for hospices across the U.S. and Canada. The mayor of San Francisco, Art Agnos, proclaimed 21 March 1989, "Colin Skinner Day," in recognition of the attention he brought to the work of hospices with AIDS patients in the city. Returning to Britain after this walk, he obtained a job as a research assistant in Chemical Pathology at the Middlesex Hospital and went on to obtain a PhD in Molecular Biology at University College London.
I think most of them would rather drink weed killer than do this." He argued that the sale would stop a one-time budget problem without addressing spending, leaving a debt bomb for future generations. The legislature sided with Kennedy, and Jindal's plan dissolved.
=== Azerbaijan === The Association of Cossacks of Azerbaijan operates in the Republic of Azerbaijan. The association was established in 1992 and registered with the Ministry of Justice of Azerbaijan on 16 November 1994, with 1,500 members. Many Cossacks under the association join the Azerbaijani Armed Forces.
Sources: en.wikipedia.org
Chick-fil-A was first introduced into the Canadian market in 1981. They opened their first locations in Oakville Place, and Burlington Centre in Ontario. These locations would later close, however it is not clear when they were shuttered. In September 1994, Chick-fil-A re-entered Canada inside a student centre food court at the University of Alberta in Edmonton, Alberta. This location did not perform very well and was closed within two or three years. The company opened an outlet at the Calgary International Airport in Alberta in May 2014, and closed it in 2019. Chick-fil-A opened a restaurant in Toronto, Ontario, on September 6, 2019, in the Yonge and Bloor Street area. There were protests criticizing the company's violation of animal rights and "history of supporting anti-LGBTQ causes". Chick-fil-A announced that it would open two other locations in Toronto during 2019, and 12 additional stores in the Greater Toronto Area over the subsequent five years. The chain's second Toronto location opened at the Yorkdale Shopping Centre in January 2020. The company expanded to other areas of Ontario in 2021, opening standalone locations with drive-through restaurants in Kitchener in August and Windsor in October. In November 2023, the first standalone with drive-through location in London was opened on Wonderland Road South. In 2024, the company opened locations in Alberta, one being in the Phase III food court of West Edmonton Mall in Edmonton. and the other being in Calgary located on Macleod Trail.
=== Hungarian === American Hungarian Catholic Society - Founded in 1894. Headquarters in Cleveland. Aside from insurance, they assist aged members, visit sick and bereaved, and provide service to local parishes. 1965 members 2,430; 1977 members 1,200. Hungarian Reformed Federation of America Verhovay Fraternal Insurance Association - Founded in Pennsylvania as Verhovay Aid Association, changed name in 1935 21,512 members at the end of 1922, and at that time was headquartered in Hazleton, Pennsylvania. It had 40,000 members in 1955 the same year it merged with William Penn William Penn Association
== Side effects == Common side effects associated with the use of flucloxacillin include: diarrhoea, nausea, rash, urticaria, pain and inflammation at injection site, superinfection (including candidiasis), allergy, and transient increases in liver enzymes and bilirubin. In fewer than 1 in 1,000 people, cholestatic jaundice (also referred to as cholestatic hepatitis) has been associated with flucloxacillin therapy. It may appear as pale stool with dark urine, and yellowish eyes and skin. The reaction may occur up to several weeks after treatment has stopped, and takes weeks to resolve. The estimated incidence is one in 15,000 exposures, and is more frequent in people over the age of 55, females, and those with a treatment duration of longer than two weeks. Flucloxacillin is contraindicated in those with a previous history of allergy to penicillins, cephalosporins, or carbapenems. It should also not be used in the eye, or administered to those with a history of cholestatic hepatitis associated with the use of dicloxacillin or flucloxacillin. It should be used with caution in the elderly, patients with renal impairment where a reduced dose is required, and those with hepatic impairment, due to the risk of cholestatic hepatitis. It should be taken on an empty stomach, as absorption is reduced when taken with food, though some studies suggest that this does not compromise flucloxacillin plasma concentrations in most circumstances.
== Further reading == Comprehensive Natural Products Chemistry, Volume 7: DNA and Aspects of Molecular Biology. Kool, Eric T., Editor. Neth. (1999), 733 pp. Publisher: (Elsevier, Amsterdam, Neth.) Beaucage, S. L.; Iyer, R. P. (1992). "Advances in the synthesis of oligonucleotides by the phosphoramidite approach". Tetrahedron. 48 (12): 2223–2311. doi:10.1016/s0040-4020(01)88752-4. Beaucage, S. L.; Iyer, R. P. (1993). "The functionalization of oligonucleotides via phosphoramidite derivatives". Tetrahedron. 49 (10): 1925–1963. doi:10.1016/s0040-4020(01)86295-5. Beaucage, S. L.; Iyer, R. P. (1993). "The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications". Tetrahedron. 49 (28): 6123–6194. doi:10.1016/s0040-4020(01)87958-8. Beaucage, S L. "Oligodeoxyribonucleotides synthesis. Phosphoramidite approach. Methods in Molecular Biology (Totowa, NJ, United States) (1993), 20 (Protocols for Oligonucleotides and Analogs), 33–61. Reese, C. B. (2002). "The chemical synthesis of oligo- and poly-nucleotides: a personal commentary". Tetrahedron. 58 (44): 8893–8920. doi:10.1016/s0040-4020(02)01084-0. Glaser, Vicki (1 May 2009). Oligo Market Benefits from RNAi Focus. Bioprocessing. Vol. 29. Mary Ann Liebert. pp. 46–49. ISSN 1935-472X. OCLC 77706455. Archived from the original on 16 April 2010. Retrieved 25 July 2009. {{cite book}}: |periodical= ignored (help)
Sources: en.wikipedia.org
Vaginal discharge may indicate a vaginal infection by color and odor, or the resulting symptoms of discharge, such as irritation or burning. Abnormal vaginal discharge may be caused by STIs, diabetes, douches, fragranced soaps, bubble baths, birth control pills, yeast infection (commonly as a result of antibiotic use) or another form of vaginitis. While vaginitis is an inflammation of the vagina, and is attributed to infection, hormonal issues, or irritants, vaginismus is an involuntary tightening of the vagina muscles during vaginal penetration that is caused by a conditioned reflex or disease. Vaginal discharge due to yeast infection is usually thick, creamy in color and odorless, while discharge due to bacterial vaginosis is gray-white in color, and discharge due to trichomoniasis is usually a gray color, thin in consistency, and has a fishy odor. Discharge in 25% of the trichomoniasis cases is yellow-green. HIV/AIDS, human papillomavirus (HPV), genital herpes and trichomoniasis are some STIs that may affect the vagina, and health sources recommend safe sex (or barrier method) practices to prevent the transmission of these and other STIs. Safe sex commonly involves the use of condoms, and sometimes female condoms (which give women more control). Both types can help avert pregnancy by preventing semen from coming in contact with the vagina.
== Scaffolds == A scaffold or matrix serves as a temporary supporting structure (extracellular matrix), the initial architecture, on which the cells can grow three-dimensionally into the desired tissue. A scaffold must provide the environment needed for cellular growth and differentiation; it must provide the strength to withstand mechanical stress and guide their growth. Moreover, scaffolds should be biodegradable and degrade at the same rate as the tissue regenerates to be optimally replaced by the host tissue. There are numerous scaffolds to choose from and when choosing a scaffold biocompatibility, porosity and stability should also be held into account. Available scaffolds for oral mucosa tissue engineering are:
Collagen, type II, alpha 1 (primary osteoarthritis, spondyloepiphyseal dysplasia, congenital), also known as COL2A1, is a human gene that provides instructions for the production of the pro-alpha1(II) chain of type II collagen.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.